TL;DR: Brands developing [acid exfoliation products](https://mastracare.com/docs-category/acid-exfoliation-technology/) for the first time tend to lose 4–6 weeks to avoidable back-and-forth during this phase
TL;DR: A brand came to us two years ago with a well-researched brief: 10% glycolic acid toner, pH 3.8, targeting the US and EU markets simultaneously
Key Technical Parameters #
Acid exfoliation formulations are technically straightforward on paper — pH, free acid fraction, concentration. Where projects actually stall is the integration step: getting a brief, a set of actives, and a target consumer experience to converge into something manufacturable, stable, and compliant before the first pilot batch is ever poured. This guide is written for brand partners who are preparing to move from concept to production with us, and it’s aimed specifically at the workflow decisions that happen before formulation work begins. Brands developing acid exfoliation products for the first time tend to lose 4–6 weeks to avoidable back-and-forth during this phase. The technical insight that changes the outcome: integration failures in acid systems are almost never about the acid itself — they’re about the matrix, the packaging, and the preservation system built around it.
Where Projects Break Down Before a Single Batch Is Made #
A brand came to us two years ago with a well-researched brief: 10% glycolic acid toner, pH 3.8, targeting the US and EU markets simultaneously. The formulation wasn’t complicated. What they hadn’t resolved — and what cost them roughly eight weeks — was that the EU launch required compliance with EU Cosmetics Regulation 1223/2009, which caps leave-on AHA products at 10% with a pH floor of 3.5 and mandates a specific on-pack sun sensitivity warning. Their US version was intended to run at pH 3.5 with the same label. Same formula, two markets, incompatible label claims. We caught it during intake. But the delay in resolving the dual-market registration knocked the launch back a full quarter.
This is the failure mode we see most often at the integration stage: not a chemistry problem, but a compliance architecture problem that nobody mapped before formulation started.
The root cause is usually scope compression. Brand owners get excited about the active and spend their energy on concentration and sensory profile. The questions that determine whether a product can actually ship — format, market, packaging material compatibility, preservation strategy, consumer positioning — get deferred. By the time they reach us, the brief is half-built.
When we receive a brief under what we internally call our FI-02 Intake Classification, the first filter isn’t pH or acid choice. It’s: does the brand understand what regulatory tier this product sits in, and across which markets? If that answer isn’t clear on the first call, we know the timeline estimate needs a buffer.
The Parameters That Actually Predict Integration Success #
Once we’ve confirmed market scope, the six parameters we evaluate in sequence are: acid identity, concentration, pH target, formulation matrix, preservation system, and primary packaging material. Most of these interact. That’s the part brands underestimate.
Acid identity and concentration set the regulatory ceiling. Glycolic acid at 10% leave-on, lactic acid up to 10%, salicylic acid at 2% in the EU — these are hard limits under the EU Cosmetics Regulation 1223/2009 and cross-referenced against SCCS Scientific Opinion assessments where applicable. For the US market, FDA currently treats most AHA/BHA cosmetics as OTC drugs only when specific drug claims are made, per FDA Cosmetics Guidelines. The distinction matters for documentation burden.
pH target is the parameter most commonly underweighted at brief stage. Below pH 3.5 in a leave-on format, you’re approaching the upper limit of what EU notifiers will accept without additional CPSR scrutiny. We’ve had CPSR assessors flag pH 3.4 glycolic acid serums as requiring additional irritation substantiation data — data that adds 3–4 weeks to the safety dossier if not planned for upfront. Above pH 4.2 in a glycolic system, free acid fraction drops steeply enough that efficacy claims become difficult to substantiate. The sweet spot for a compliant, efficacious leave-on is narrow: roughly pH 3.5–4.0.
Matrix viscosity affects penetration depth and rinse-off profile. This is where we often push back on briefs that ask for “serum texture, strong exfoliation.” Thin serums with low molecular weight humectants accelerate acid penetration — which is fine in a clinic protocol, not always appropriate for a daily-use consumer product. We’d rather formulate at pH 3.8 in a slightly viscous matrix than push pH lower to compensate for reduced residence time.
Preservation system in acid products is genuinely tricky. Low pH creates a challenging environment for some traditional preservatives. Phenoxyethanol is stable across the pH range we work in. Parabens retain activity but face marketing headwinds — and in our experience, the conversation about “paraben-free” is almost always a marketing decision disguised as a formulation request. Sodium benzoate and potassium sorbate are pH-dependent; below pH 4.5 they’re effective, above that they lose activity fast. Our standard approach in AHA serums is phenoxyethanol at 0.8–1.0% with ethylhexylglycerin as a booster, confirmed via challenge testing to ISO Standards ISO 11930.
Primary packaging is where integration failures hide. Aluminum tubes are problematic with low-pH AHA formulations above roughly 8% concentration — we’ve seen inner lacquer degradation at the 12-week accelerated stability mark in two separate projects when brands pushed glycolic above 12% in aluminum with compromised lacquer coating. Glass and HDPE/PP are preferred. PET is acceptable at pH above 3.8. Below that, we flag it in every qualification review.
| Parameter | Recommended Range (Leave-On AHA) | Common Brief Error | Integration Risk |
|---|---|---|---|
| pH | 3.5–4.0 | Targeting pH 3.2–3.4 for “stronger effect” | EU CPSR flag; increased irritation potential |
| Glycolic Acid Concentration | 5–10% | Requesting 12–15% leave-on | Exceeds EU regulatory ceiling; stability issues |
| Phenoxyethanol (Preservative) | 0.8–1.0% | Omitting preservative challenge plan | Challenge test failure; batch rejection |
| Packaging Material | Glass, HDPE, PP | Aluminum tube with thin inner lacquer | Lacquer degradation at 12-week accelerated test |
| Viscosity (leave-on serum) | 500–3,000 mPa·s | Ultra-low viscosity “water texture” brief | Excessive penetration depth; consumer tolerance issues |
The most commonly overlooked parameter in our intake reviews is packaging material. Teams spend hours on the actives and five minutes on the container. The container is what the formulation lives in for 24 months.
Integration Decision Framework: Four Scenarios We See Repeatedly #
If the brief targets both EU and US simultaneously with a single formula, the approach is to design to the stricter constraint first — EU — and verify US compliance is met by default. This holds for glycolic and lactic acid systems where EU limits are lower than common US practice. For salicylic acid, the alignment is close enough that a single formula at 1.5–2.0% at pH 3.8–4.2 clears both markets in a leave-on serum format. Design to EU, ship globally.
If the brief requests a “peel-strength” feel in a retail leave-on format, we almost always reframe this during kickoff. A 2020 randomized split-face study (n=44, 8 weeks) comparing 10% glycolic acid leave-on at pH 3.5 versus 3.8 showed 22% improvement in skin texture scores at the lower pH but also a 31% higher incidence of transient erythema within the first three weeks of use. The texture improvement was meaningful. The tolerability gap was also meaningful. For a mass-market consumer brief, we’d recommend pH 3.7–3.8 with a 10% glycolic concentration rather than chasing pH 3.5, unless the brand’s consumer skews experienced and the packaging supports the positioning.
If the brand wants to combine AHAs with a niacinamide brightening claim in the same formula, the approach changes because of the niacinamide-acid interaction at low pH. Below pH 3.8, niacinamide conversion to niacin accelerates — and the flush risk, while rarely severe in a serum, creates a consumer experience problem. Our internal testing across 11 formulation iterations showed stable niacinamide performance down to pH 3.9 when concentration is held at 3–4%. Below that threshold, we recommend either a separate product step or shifting to a different brightening agent in the acid formula. Some brands insist on the combination. We support it, but we document the pH boundary in the brief.
If timeline is compressed to under 12 weeks for a first acid product, the formulation work itself is achievable. What compresses first is the stability package. Accelerated stability at 40°C/75% RH gives you 6-month predictive data in 4–8 weeks, but real-time 24-month data requires concurrent initiation from Day 1. We’ve had brands request 8-week turnaround and then discover at month 14 that pH drift exceeded specification — a problem that was detectable at week 4 if the stability protocol had been set up properly at brief intake. The specific recommendation: initiate real-time stability the same week as pilot batch production, regardless of how confident the accelerated data looks.
One scenario we don’t have fully resolved: combination briefs requesting AHA plus encapsulated retinol in a single leave-on formula. Our encapsulation technology work shows reasonable retinol protection down to pH 4.0, but below that the capsule wall integrity becomes variable depending on supplier and batch. We’re still building that dataset. For now, we recommend keeping these as separate SKUs or sequential-step systems until we have stability data across a broader pH range.
Formulation Notes for Brand Partners #
When you brief us on an acid exfoliation product, the first questions we’ll ask are: which market, which format (rinse-off or leave-on), and what the on-pack story is. Those three answers determine the entire integration pathway before we touch a single ingredient.
The most common mistake we see in incoming briefs is under-specifying the market while over-specifying the sensory experience. A brief that says “we want something that tingles and feels clinical” without naming the target regulatory market creates significant rework downstream. We’ll push you to resolve this upfront, because the EU, US, and China NMPA pathways have different documentation requirements and different concentration ceilings for the same actives.
On timeline: lab samples are typically ready in 2–3 weeks from brief sign-off. Accelerated stability runs 4–8 weeks and gives us early confidence data. Real-time 24-month stability starts concurrently from the pilot batch date. If you’re targeting EU launch, factor in CPSR preparation time separately — for straightforward AHA products at compliant concentrations, CPSR turnaround with our standard safety partners runs 3–5 weeks. For novel combinations or borderline pH specifications, allow 6–8 weeks. Don’t plan a launch date without confirming where in the CPSR queue you sit.
Frequently Asked Questions #
We want 10% glycolic acid at pH 3.5 — can you make it and ship to the EU?
A: Technically yes, the concentration is within EU limits, but pH 3.5 in a leave-on product will draw additional scrutiny from your CPSR assessor, and you’ll likely need supplementary irritation substantiation data. If there’s flexibility, formulating at pH 3.7–3.8 simplifies the safety file considerably and the efficacy difference is smaller than most people expect.
Does China NMPA require anything different for AHA products compared to the EU?
A: Yes — NMPA Cosmetic Regulation classifies AHA products above certain concentrations as “special use cosmetics,” which triggers a separate registration track with additional clinical documentation requirements. The threshold and classification details shift periodically, so we verify current status for every China-bound brief before formulation starts. Budget an additional 4–8 weeks for the registration pathway if you’re targeting China.
We sent you a formula from another supplier — can you just run it? What could go wrong?
A: We can, but we’ll run it through our FI-02 intake process first. The failure mode we see most often with transferred AHA formulas is preservation system incompatibility that wasn’t caught in the original supplier’s challenge testing. Low-pH environments stress some preservative systems, and a formula that passed challenge testing at one manufacturer’s conditions may fail at ours due to water activity or processing temperature differences. We’ll always run ISO 11930 challenge testing on transferred formulas before committing to production.
What’s the minimum order quantity for a first acid serum, and how long does full qualification take?
A: MOQ on a standard leave-on AHA serum is typically 500kg per SKU for a new project. Full qualification — including lab sample approval, accelerated stability data, and primary packaging compatibility — runs approximately 10–14 weeks from signed brief. That assumes a single target market. Dual-market briefs (EU + US) add 2–3 weeks for documentation alignment.
Is there something we should be asking that we’re not?
A: Packaging timeline. Most brands lock the formulation before the primary packaging lead time is confirmed, then discover their preferred pump or glass bottle has a 10–12 week supply lead time in Asia. We’ve seen launches delayed not by formulation or stability, but because the bottle wasn’t ordered until after sample approval. Ask your packaging supplier for committed lead times before you approve the formula — running those two workstreams in parallel saves real calendar time.
Have a product concept in mind? Contact our formulation team to request a complimentary brief review.
The pH floor piece is what catches brands off guard most often — a 10% glycolic leave-on at pH 3.4 might feel more efficacious to the formulator, but the moment you need a Consumer Safety Assessment signed off under 1223/2009, that sub-3.5 pH becomes a flagged parameter and you’re redoing stability and irritation data. We’ve seen “clinically tested exfoliant” copy get pulled two weeks before launch because the patch test panel didn’t reflect the final formula pH.
The dual-market brief scenario is painfully familiar — we’ve had clients spec identical US/EU SKUs only to absorb the cost of two separate CPSRs plus a reformulation round when the pH floor forces a composition change. That’s easily €4,000–6,000 in assessment fees alone before stability retesting, and most brands didn’t budget for it because nobody flagged the Regulation 1223/2009 ceiling as a line item during scoping.
Our Shenzhen OEM flagged the phenoxyethanol at 0.8% as “too low for their standard process” and pushed to run it at 1.2% — which would’ve sailed straight past the EU ceiling and killed the CPSR before we even had a draft. Took three rounds of back-and-forth over about five weeks before they accepted the challenge test data as justification for holding the lower level.
Signed brief to approved pilot took us eleven months on a lactic acid body lotion, and honestly the packaging compatibility piece added six weeks we hadn’t budgeted — the low-pH formula was etching the inner coating on the supplier’s standard HDPE cap, which nobody flagged until stability samples came back cloudy at week eight.
Stability is the part that blindsided us — we assumed a glycolic toner at pH 3.8 would be relatively inert, but our 12-week real-time data at 25°C showed measurable pH drift upward, which pushed free acid fraction down enough to raise efficacy questions before we’d even touched clinical. We ended up running a concurrent photostability screen after the SPF warning requirement flagged a potential interaction with the UV-absorbing fragrance component we’d specced in.
When you’re running a dual-market SKU at exactly pH 3.5, does the EU Cosmetics Regulation 1223/2009 sun sensitivity warning need to appear on the US version too, or can the label diverge at that point without triggering a separate stability and compliance review for each market?
The matrix piece is what we kept underestimating — our first glycolic brief had a beautifully dialed pH but we’d spec’d a frosted PET bottle that started showing micro-crazing at 40°C accelerated, which pushed us back to a glass alternative and added five weeks before we’d even touched the formula.
The preservative challenge plan gap is something we kept treating as a late-stage item — submitted our first glycolic toner brief with phenoxyethanol at 0.9% and genuinely assumed that was enough to move forward, then watched six weeks disappear when our manufacturer’s QA team required a full ISO 11930 challenge test before they’d greenlight the pilot, which nobody on our side had scheduled into the timeline.
Worth flagging for anyone selling into ASEAN markets — Thailand’s FDA classifies leave-on AHA products above 10% as a “specially controlled cosmetic,” which triggers a separate notification pathway and requires a local Responsible Person entity before you can even submit. We burned nearly three months on a glycolic serum brief because our client assumed the EU CPSR documentation would transfer directly, and the Thai FDA doesn’t recognize it.